Remdesivir, the drug closest to approval for COVID-19 treatment, and the first clinical results

We have been facing this pandemic for only 4 months, but because of its seriousness, the search for new treatments is continuing more intensively than for any disease in history. Everyone is wondering about COVID-19 caused by the novel coronavirus and when a specific treatment will become available. Although approval of a new drug or treatment normally takes 5-10 years, it is very clear that the world does not have that much time in this pandemic.
The United States Food and Drug Administration (FDA) uses the terms "Expanded Access" or "Compassionate Use" to describe the use of unapproved drugs or medical devices in severely ill patients with life-threatening conditions. Remdesivir, during the COVID-19 pandemic, is one of the drugs physicians use for patients in serious condition. On 10 April 2020, New England Journal of Medicine, one of medicine's leading scientific journals, published promising remdesivir results in patients with severe COVID-19 from a clinical trial conducted from 25 January to 7 March 2020 with a total of 61 patients.
How does remdesivir exert its antiviral effect?
Remdesivir is a prodrug metabolized inside cells into its active form, an adenosine triphosphate analogue; it is administered by intravenous infusion. This compound acts by inhibiting an enzyme called viral RNA polymerase. Remdesivir's activity against various virus families, including filoviruses such as Ebola and coronaviruses such as SARS-CoV and MERS-CoV, had previously been demonstrated in vitro, in the laboratory. In recent months, in-vitro studies also demonstrated activity against the novel coronavirus, SARS-CoV-2.
According to previous studies involving approximately 500 people, including healthy volunteers and patients treated for acute Ebola infection, remdesivir appears to have a suitable clinical safety profile.
Some medical terms used in this article:
- Intubation: Placing a tube, an endotracheal tube, into a patient's windpipe after inducing sleep with anesthesia. It provides a secure pathway for breathing air between a mechanical ventilator and a patient with respiratory failure.
- Extubation: Removing the endotracheal tube and disconnecting the patient from the ventilator.
- Invasive mechanical ventilation: Using a mechanical ventilator, or breathing machine, to perform breathing for a patient after intubation.
- Non-invasive mechanical ventilation: Providing breathing support to a patient who is not intubated using a ventilator and a special mask.
The following criteria were used to identify eligible COVID-19 patients:
- Being hospitalized,
- RT-PCR (Reverse-Transcriptase Polymerase Chain Reaction) test-confirmed SARS-CoV-2 infection,
- An oxygen saturation of 94% or less while breathing room air, or a need for supplemental oxygen.
- A GFR (glomerular filtration rate) of 30 ml or above, and ALT and AST levels less than 5 times the upper limit of normal, meaning no kidney or liver failure in the blood test results.
Before going into the details of the remdesivir study, let us present its clinical results at the beginning of this article:
The effect of remdesivir on clinical improvement

Figure 1. Oxygen-support status at baseline and after treatment. Patient percentages for each oxygen-support category were calculated according to the baseline patient categories. Improvement in oxygen support is shown in blue, no change in beige, and worsening in gray. Invasive ventilation includes invasive mechanical ventilation and ECMO; noninvasive ventilation includes nasal high-flow oxygen support and noninvasive positive-pressure ventilation.
During a median follow-up of 18 days after the first remdesivir dose, 36 of 53 patients (68%) improved in oxygen-support category, while 8 (15%) worsened. Improvement was recorded in all 12 patients breathing room air or receiving low-flow oxygen, and in 5 of 7 patients receiving noninvasive ventilation, positive-pressure ventilator support without intubation.
Notably, 17 of 30 patients (57%) receiving invasive ventilation, who were intubated, were extubated, and 3 of the 4 patients receiving ECMO no longer needed it.
At the latest follow-up, 25 of 53 patients had been discharged: 8 of the 34 receiving invasive ventilation and 17 of the 19 receiving noninvasive oxygen support. Statistical analysis showed an overall clinical improvement of 84% (95%; 70-99) after 28 days of follow-up.
Effect on mortality (death rate)
Of the 53 patients who completed the remdesivir treatment regimen, 7 (13%) died: 6 of the 34 receiving invasive ventilation and 1 of the 19 receiving noninvasive oxygen support. Mortality was much higher in those aged 70 and older (hazard ratio 11.34; 95%, 1.36-94.17).
Study details
The treatment plan for patients enrolled in the study was a 200 mg intravenous loading dose on the first day, followed by 100 mg intravenous remdesivir 1 time a day for 9 days. Other supportive treatments were left to the physician's judgment and methods. Follow-up was set at 28 days from the start of remdesivir treatment, or until discharge or death.
The study analyzed major clinical events in the patients. These included their need for respiratory support: breathing room air, low-flow oxygen treatment, nasal high-flow oxygen treatment, noninvasive positive-pressure ventilation, invasive mechanical ventilation and extracorporeal membrane oxygenation (ECMO); hospital discharge; reported adverse effects; and death. The investigators calculated the proportion of patients who showed clinical improvement. They defined clinical improvement as discharge from hospital and/or a decrease of 2 categories from baseline on the modified ordinal scale recommended by WHO and the R&D Blueprint Group.
The modified ordinal scale consists of the following categories:
- No need for inpatient hospital treatment
- Requiring inpatient hospital treatment but no oxygen support
- Requiring inpatient hospital treatment and oxygen support
- Requiring inpatient hospital treatment and nasal high-flow oxygen and/or noninvasive mechanical ventilation
- Requiring inpatient hospital treatment and invasive mechanical ventilation and/or ECMO
- Death
A total of 61 patients received at least one dose of remdesivir before 7 March 2020. Of these, 7 were excluded because of insufficient data after the baseline report and 1 because the remdesivir start date had been reported incorrectly. Of the remaining 53 patients, 40 (75%) completed 10 days of remdesivir treatment, 10 (19%) received it for 5 to 9 days, and 3 (6%) received it for fewer than 5 days. The patients came from the United States (22), Japan (9), Italy (12), Austria (1), France (4), Germany (2), the Netherlands (1), Spain (1) and Canada (1).
Of the patients, 40 (75%) were men; ages ranged from 23 to 82, with a median age of 64. Most patients, 34 (64%), initially required invasive ventilation: 30 were managed with mechanical ventilation and 4 with ECMO. The median duration of invasive mechanical ventilation before starting remdesivir was 2 days. Patients initially requiring invasive ventilation tended to be older, with median ages of 67 versus 53; male, 79% versus 68%; and to have higher serum ALT, 48 U/L versus 27 U/L, and creatinine, 0.90 mg/dL versus 0.79 mg/dL. They also tended to have more frequent comorbidities: hypertension, 26% versus 21%; diabetes mellitus, 24% versus 5%; hyperlipidemia, 18% versus 0%; and asthma, 15% versus 5%. The median duration of symptoms before treatment was 12 days, with no significant difference between patients receiving invasive and noninvasive ventilation.
Safety / adverse effects
Adverse effects were observed in 32 patients (60%). The most common were elevated liver enzymes, diarrhea, kidney failure and hypotension. Adverse effects were generally more frequent in patients receiving invasive ventilation. Serious adverse effects, including multiple organ failure, septic shock, acute kidney injury and hypotension, were reported in 12 patients (23%). Because of the severity of adverse effects, 4 patients (8%) could not continue remdesivir treatment.
Conclusion
This study reports observations of remdesivir treatment in a small group of patients with severe COVID-19. Larger randomized, placebo-controlled studies are ongoing and will soon provide stronger evidence. However, this report presents the best currently available data from COVID-19 treatment studies. During a median follow-up of 18 days, reduced oxygen support was observed in 68% of patients, and overall mortality was 13%. In a recent placebo-controlled randomized clinical trial of lopinavir and ritonavir, 28-day mortality was 22%. It should be noted that only 1 of the 199 patients in that trial was receiving invasive ventilation at baseline. Case series and cohort studies, mostly conducted in China, have reported mortality rates ranging from 17% to 78%. In a Wuhan study of 201 patients receiving invasive ventilation, mortality was reported as 22%. In this context, the mortality rate in this remdesivir study, 13%, may be meaningful when the severity of participants' illness is considered. However, the short follow-up, small number of participants, possible data loss and differences between clinics in other supportive treatments must be considered. Until other factors that could have produced this situation are excluded through larger randomized, placebo-controlled clinical trials, the level of evidence in this report remains relatively low.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.